Form 8K Terns Pharmaceuticals Inc For: 5 May
- Investing.com
Future Catalysts | Upcoming trial results and potential partnerships could significantly impact stock performance, with analyst price targets ranging from $15 to $20 |
Market Dynamics | Explore how Terns navigates competitive CML and obesity treatment landscapes, with analysts noting potential for significant market share capture |
Financial Health | Strong cash position of $315 million provides runway into 2028, supporting ongoing clinical trials without immediate financing concerns |
Promising Pipeline | Terns Pharmaceuticals' TERN-701 for CML and TERN-601 for obesity show potential to disrupt markets, with key data readouts expected in Q4 2025 |
Metrics to compare | TERN | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipTERNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −1.4x | −0.3x | |
PEG Ratio | 0.00 | −0.04 | 0.00 | |
Price / Book | 0.0x | 2.3x | 2.6x | |
Price / LTM Sales | 0.0x | 11.1x | 3.0x | |
Upside (Analyst Target) | 0.0% | 77.5% | 59.8% | |
Fair Value Upside | Unlock | −2.3% | 7.1% | Unlock |